Overall, the data from the CDK18 activation clones is consistent with our findings in breast cancer clinical cohorts, where elevated levels of endogenous CDK18 protein expression confers an improved repose to chemotherapeutic agents that induce high levels of replication stress. The gene discussed is CDK18; the disease is breast cancer.